ABT-089 (pozanicline) is a partial agonist at α4β2 nAChRs, the high-affinity nicotinic subtype that nicotine primarily acts on for attentional and working memory effects. Partial agonism at α4β2 activates the receptor while competing with full agonists at the binding site, which paradoxically reduces desensitization relative to nicotine: the partial agonist occupies the receptor without driving the maximal conformational change that leads to the desensitized state. The result is tighter attentional filtering and improved prefrontal acetylcholine signaling with a cleaner durability profile than nicotine.
The stack logic with Tropisetron is simple: Tropisetron targets α7 nAChRs (sensory gating, signal-to-noise ratio), ABT-089 targets α4β2 (sustained attention, working memory bandwidth). Different subunits, no competition, distinct cognitive profiles.
together they cover both major nicotinic subtypes in the CNS. ABT-089 reached Phase II trials for ADHD and mild cognitive impairment before being dropped for commercial rather than safety reasons. Human trial doses ran 1–5mg; subjective profile is mild and not immediately felt, accumulating over days.